Pennsylvania is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
SHAPE of Portal Hypertension in Children
NCT04720456
Recruiting
Early diagnosis of portal hypertension is difficult as symptoms rarely manifest until the later stages of liver disease. Both cirrhotic and non-cirrhotic portal hypertension can result in life-threatening complications, the most frequent of which is bleeding from esophageal varices. In children, variceal bleeds are associated with mortality rates of 1-3 %, while life-threatening complications have been reported in up to 20 % of children with cirrhosis. Despite the high incidence of portal hypert... Read More
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
02/07/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Hypertension, Portal
Register for Updates
Functional Recovery After Total Knee Arthroplasty
NCT06821269
Recruiting
The goal of this observational study is to learn about patients' recoveries after receiving total knee arthroplasty (TKA). The main questions it aims to answer are: Does robotic-assisted TKA have improved perceived recovery when compared to conventional TKA? Does robotic-assisted TKA lead to improved functional recovery when compared to conventional TKA? Researchers will compare if robotic-assisted versus conventional procedures lead to different recovery speeds. Participants will answer ques... Read More
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
02/06/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Arthritis Knee
Register for Updates
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
NCT06498661
Recruiting
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a common virus which usually causes infections that last only a few months, but sometimes can last longer. It is known to cause a variety of cancers including cancer of the cervix. Even though there are ways to detect cervical cancer early, many individuals do not un... Read More
Gender:
FEMALE
Ages:
25 years and above
Trial Updated:
02/06/2025
Locations: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Register for Updates
Virtual Patient Navigation During a Pandemic
NCT06208852
Recruiting
The sub-study will involve a rigorous mixed-methods design. The qualitative phase of the sub-study will consist of semi-structured interviews. During the semi-structured interviews, 10 eligible women will be recruited to identify barriers and facilitators to accessing virtual mental health services. This information will be used to adapt an evidence-based patient navigation intervention for virtual use. For the intervention phase of the sub-study, 30 women with persistent postpartum depression s... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Post-partum Depression
Register for Updates
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
NCT06122077
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/06/2025
Locations: Clinical Research Associates of Central PA, DuBois, Pennsylvania
Conditions: Lung Cancer Diagnosis
Register for Updates
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
NCT06052839
Recruiting
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 monoclonal antibody (mAb) therapy and that chemotherapy given after anti-PD-1 mAb therapy is associated with higher efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Register for Updates
Optimizing CAB-LA As PrEP for Women Who Inject Drugs
NCT05799339
Recruiting
The goal of this study is to elicit information crucial for designing strategies to support engagement in cabotegravir, a long-acting injectable form of pre-exposure prophylaxis (PrEP) to reduce HIV risk among women who inject drugs (WWID), a population with high unmet need that has been understudied in all phases of PrEP research. The main questions this study aims to answer are: 1. How do WWID perceive long-acting injectable cabotegravir (CAB-LA) as a HIV prevention tool? 2. If and how their... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Prevention Point Philadelphia, Philadelphia, Pennsylvania
Conditions: HIV Infections, Opioid Use, Trauma, Psychological
Register for Updates
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196
Recruiting
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Gender:
ALL
Ages:
1 year and below
Trial Updated:
02/06/2025
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
Register for Updates
Regeneration of Acutely Injured Nerves with Temporary Electrical Stimulation
NCT05721261
Recruiting
A novel temporary peripheral nerve stimulation system that delivers a single dose of electrical stimulation therapy for 1 hour will be evaluated for safety and effectiveness.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/06/2025
Locations: WellSpan Health, York, Pennsylvania
Conditions: Nerve Injury
Register for Updates
Reduced-dose Botox for Urgency Incontinence Among Elder Females
NCT05512039
Recruiting
The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
Gender:
FEMALE
Ages:
70 years and above
Trial Updated:
02/06/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
Register for Updates
EyeConic: Qualification for Cone-Optogenetics
NCT05294978
Recruiting
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2025
Locations: University of Pittsburgh, Department of Ophthalmology, Pittsburgh, Pennsylvania
Conditions: Retinal Dystrophies
Register for Updates
FTT PET/CT in Metastatic Prostate Cancer
NCT05242744
Recruiting
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer. Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment. Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: University of Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Prostate Cancer Metastatic
Register for Updates